Black Diamond Therapeutics, Inc. (BDTX)
1.805
-0.14
(-6.96%)
USD |
NASDAQ |
Oct 06, 16:00
1.805
0.00 (0.00%)
After-Hours: 18:38
Black Diamond Therapeutics Shareholders Equity (Quarterly) : 96.09M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 96.09M |
| March 31, 2026 | 104.30M |
| December 31, 2025 | 112.21M |
| September 30, 2025 | 126.15M |
| June 30, 2025 | 132.61M |
| March 31, 2025 | 141.52M |
| December 31, 2024 | 83.28M |
| September 30, 2024 | 97.43M |
| June 30, 2024 | 111.02M |
| March 31, 2024 | 104.31M |
| December 31, 2023 | 116.74M |
| September 30, 2023 | 134.32M |
| June 30, 2023 | 82.20M |
| March 31, 2023 | 98.19M |
| December 31, 2022 | 115.70M |
| September 30, 2022 | 133.23M |
| Date | Value |
|---|---|
| June 30, 2022 | 152.37M |
| March 31, 2022 | 172.56M |
| December 31, 2021 | 195.90M |
| September 30, 2021 | 218.95M |
| June 30, 2021 | 251.02M |
| March 31, 2021 | 280.75M |
| December 31, 2020 | 307.76M |
| September 30, 2020 | 327.34M |
| June 30, 2020 | 343.12M |
| March 31, 2020 | 355.26M |
| December 31, 2019 | -47.16M |
| September 30, 2019 | -39.79M |
| June 30, 2019 | 0.00 |
| March 31, 2019 | |
| December 31, 2018 | -15.54M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
| BioCryst Pharmaceuticals, Inc. | -454.29M |
| Imunon, Inc. | 4.189M |
| Curis, Inc. | 4.695M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 125.03M |
| Total Liabilities (Quarterly) | 28.94M |
| Debt to Equity Ratio | 0.1766 |
| Current Ratio | 7.284 |
| Net Debt Paydown Yield | 0.87% |